Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1715 - A phase IIA dose optimization study of ASLAN003 in acute myeloid leukemia (AML)


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research


Tumour Site



Chin Hin Ng


Annals of Oncology (2018) 29 (suppl_8): viii359-viii371. 10.1093/annonc/mdy286


C.H. Ng1, S.B. Ting2, W.Y.K. Hwang3, A. Bajel4, R. Eek5, M. McHale6, H. Shih7, N. McIntyre8, J. Kwek9, B. Lindmark6

Author affiliations

  • 1 Haematology-oncology, National University Hospital, 119074 - Singapore/SG
  • 2 Haematology Department, Eastern Health, Box Hill Hospital, Box Hill/AU
  • 3 Haematology, Singapore General Hospital and National Cancer Centre, Singapore/SG
  • 4 Department Of Clinical Haematology, Royal Melbourne Hospital, Parkville /AU
  • 5 Medical Oncology, Border Medical Oncology Research Unit, Albury/AU
  • 6 Medical, ASLAN Pharmaceuticals, 89824 - Singapore/SG
  • 7 Medical, ASLAN Pharmaceuticals, 110 - Taipei/TW
  • 8 Statistical, ASLAN Pharmaceuticals, 89824 - Singapore/SG
  • 9 Clinical Operations, ASLAN Pharmaceuticals, 89824 - Singapore/SG


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1715


AML is a heterogeneous hematologic malignancy. For patients who are ineligible for standard treatment, relapsed from prior remission, or failed prior treatment, only few options are available for further treatment and the responses are limited. A recent study has identified dihydroorate dehydrogenase (DHODH) as a critical enzyme in the myeloid differentiation of human AML blast. At present there is no specific molecular marker to identify likely responders to DHODH inhibition. ASLAN003, a potent small molecular DHODH inhibitor, which has completed phase 1, has demonstrated the ability to induce differentiation in AML cell lines, xenograft models, and the primary AML blast obtained from patients. ASLAN003 has shown a safe and tolerable profile in prior phase I studies.

Trial design

A multicenter, single arm phase IIA study to evaluate ASLAN003 as monotherapy in patients with AML who are ineligible for standard therapy. The primary objective is to determine the optimum dose of ASLAN003 based on the efficacy, safety and tolerability profile, of doses already studied in healthy volunteers. Safety will be assessed based on Adverse Events and other safety measures including vital signs, laboratory tests, electrocardiography. Efficacy will be assessed using the Overall Complete Remission Rate (OCRR, % of complete remission (CR) + complete remission with incomplete hematologic recovery (CRi)). Secondary objective is to assess the pharmacokinetics (PKs) of ASLAN003 and its metabolite and to further assess the efficacy based on relapse-free survival and clinical benefit rate (CBR, % of partial remission +CR+ CRi). Exploratory objectives is to exam the myeloid differentiation effects of ASLAN003 ex vivo and explore the possible relationships between the clinical response and AML molecular profile. The study contains 3 cohorts (ASLAN003 100 mg, 200 mg, and 300 mg once daily). Accrual has started on December 2017, with planned enrollment for 6 patients for each cohort. Safety data will be listed and summarized. Overall AML response data will be listed and summarized showing frequency and proportion of the best response, OCRR and CBR by dose levels. Concentrations and PK parameters will be listed and summarized using descriptive statistics.

Clinical trial identification

Clinical trial information: NCT03451084.

Legal entity responsible for the study

ASLAN Pharmaceuticals.


ASLAN Pharmaceuticals.

Editorial Acknowledgement


M. McHale: Chief Operating Officer and holds stocks: ASLAN Pharmaceuticals. H-J. Shih, J. Kwek: Employee: ASLAN Pharmaceuticals. N. McIntyre: Statistical consultant: Aslan Pharmaceuticals. B. Lindmark: Employee, senior management team and CMO: ASLAN Pharmaceuticals; Holds stock and stock options: ASLAN Pharmaceuticals. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.